Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), an Israel-based clinical-stage biotechnology company, announced on Monday that it has named Matthew Frankel, MD, MBA as its new chief medical officer (CMO) and vice president of Drug Development.
DrFrankel has held the position of vice president, Clinical Development and Medical Affairs, Specialty Pharma at Boehringer Ingelheim. He has served as vice president & head, Immunology and Dermatology Medical Unit at Novartis. He has served in clinical development leadership roles across geographies and therapeutic disease areas at Reata, Fibrogen, Abbotts Labs, and Schering Plough.
Dr Frankel holds a BA degree from Vassar College, an MD degree from the University of California School of Medicine, Los Angeles and an MBA from the J L Kellogg Graduate School of Management at Northwestern University.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer